CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $524 millionEC and U.S. FDA label updates for CARVYKTI® to include overall survival benefit versus standard of care Ov ...
Now, let's delve into solving the Biotech crops crossword clue, featured as 49 Down in the USA Today Crossword on November 9, ...
Breakthrough Properties' eight-story life sciences building at 2300 Market St. welcomed a big addition on Thursday.
1don MSN
If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk the uptick in biotech and pharma M&A, what it is signaling, and how to play it ...
Picture a world where most life-saving medicines are discovered not in the United States, but in Beijing and Shanghai. Imagine a time when the most advanced biotechnologies, therapies that cure ...
The drug development funding playbook that worked for decades is now in trouble, University of Pennsylvania Perelman School ...
Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, ...
The FDA has put a clinical hold on a Tenaya Therapeutics gene therapy study | The FDA has put a clinical hold on a Tenaya ...
SOMERSET, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a U.S.-based global leader in cell therapy, today announced the official opening and ...
The research-focused Core Access Fund recently awarded its first two startups and hopes to support more in the future.
Oliver Barnes Pfizer and Novo Nordisk duked it out for who will own Metsera — a coveted biotech that’s developing ...
Pfizer is launching the first clinical trials for its PD-1xVEGF drug, while Akeso detailed the first overall survival win for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback